Skip to main content

Notice for crisantaspase (PPD Australia Pty Ltd)

Active ingredients
crisantaspase
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
lyophilized powder for solution for injection/infusion
Indication
Indicated in combination with other chemotherapeutic agents to treat patients with paediatric acute lymphoblastic leukaemia (ALL)
Therapeutic area
Oncology

Help us improve the Therapeutic Goods Administration site